InterMune (ITMN -16.4%) tumbles on news that a key clinical trial for its respiratory drug...
InterMune (ITMN -16.4%) tumbles on news that a key clinical trial for its respiratory drug Esbriet has been delayed. Last week, ITMN said it didn't expect enrollment for the Phase 3 clinical trial to be completed until the end of 2012; it had previously forecast enrollment would be completed in Q2. Citing the delay, Jefferies and Leerink Swann cut price targets on the shares.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at CNBC.com (Sep 15, 2014)
at CNBC.com (Sep 11, 2014)
at MarketWatch.com (Sep 11, 2014)
at CNBC.com (Aug 28, 2014)
at CNBC.com (Aug 26, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs